Global Pharmacovigilance Market Size, Share & Forecast, By Service Type, Delivery Model & End User, 2026–2031

The Global Pharmacovigilance Market was valued at USD 9,350 million in 2025. The estimate includes outsourced and in-house pharmacovigilance services, safety database and workflow solutions, individual case processing, aggregate reporting, signal management, literature surveillance and risk-management support. Phase IV and post-marketing activities represent the largest revenue pool because safety obligations continue throughout the commercial life of medicines. The estimate excludes internal safety work that does not generate an identifiable service or technology revenue stream.

The market is forecast to reach USD 18,260 million by 2031, representing an 11.78% CAGR from 2026 through 2031. Growth will be driven by higher clinical and commercial safety-case volumes, broader regulatory coverage, increased outsourcing and adoption of AI-assisted workflows. Higher-value services such as signal validation, risk-management planning, real-world evidence and aggregate benefit-risk reporting are expected to grow faster than routine data entry. Forecast performance assumes continued pharmaceutical development activity and no material weakening of mandatory safety-surveillance requirements.

Profit pools will shift from manual case entry toward medical review, signal analytics, risk management, regulatory intelligence and validated automation. Routine case-processing prices will face pressure as sponsors standardize workflows and source capacity from global delivery centers. In contrast, complex biologics, advanced therapies, multilingual literature and real-world evidence require scarce clinical and technical expertise. Technology vendors can capture subscription and transaction revenue, while service providers can defend margins through integrated platforms, outcome-based contracts and faster signal-resolution performance.

The most significant risk is failure to identify, evaluate or report safety information accurately within required timelines. Underreporting can obscure emerging risks, while duplicate or incomplete cases can create false signals and unnecessary medical-review costs. Regulatory fragmentation adds complexity because seriousness, expectedness, privacy and reporting rules differ by jurisdiction. AI introduces an additional control challenge because plausible but incorrect outputs are unacceptable in safety-critical workflows. Providers therefore require validated systems, qualified personnel, reconciliation controls, audit trails and documented human oversight.

The United States offers the largest current revenue pool, while China, Germany, Japan, the United Kingdom and India provide strategically relevant expansion opportunities. The United States benefits from pharmaceutical scale and mature FDA requirements. Germany and the United Kingdom combine established regulators with sophisticated sponsor demand. China offers a large and expanding domestic pharmaceutical base. India has a smaller direct market but is strategically important as a global case-processing, technology and functional-service delivery hub, supported by experienced life-sciences talent.

The primary demand driver is the continuing expansion of clinical-development and marketed-product portfolios subject to mandatory safety surveillance. Each new trial, product approval, indication expansion and geographic launch creates additional case intake, follow-up, reporting, aggregate analysis and signal-management work. recorded 563,828 registered studies by the end of 2025, while FDA approved 46 novel drugs during the year. Complex oncology, biologic, vaccine and advanced-therapy products further increase the medical expertise required per case.

Sponsors should prioritize regulatory coverage, medical depth, validated technology, measurable quality and scalable operating capacity. A qualified partner must support case intake, coding, follow-up, submissions, signal management, aggregate reporting and inspection readiness across relevant jurisdictions. Buyers should examine accuracy, timeliness, staff turnover, signal cycle time, business continuity and integration with clinical, regulatory and medical-information systems. Automation should be assessed through documented validation and human oversight rather than headline productivity claims alone.